ESPR — Esperion Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1434868 ·
Last close
$3.12
Market Cap
$803.19M
52W High
$3.39
52W Low
$1.80
ADV30
16,993,678
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 80,104,000 | 45,531,000 | -6,581,000 | -25,196,000 | 462,529,000 | 156,158,000 | 770,460,000 |
| Dec 2025 | 168,446,000 | 140,592,000 | 85,233,000 | 61,831,000 | 465,886,000 | 167,852,000 | 767,851,000 |
| Sep 2025 | 87,309,000 | 46,020,000 | -9,959,000 | -31,333,000 | 364,020,000 | 92,447,000 | 815,381,000 |
| Jun 2025 | 82,385,000 | 53,842,000 | 7,095,000 | -12,725,000 | 347,085,000 | 86,061,000 | 780,594,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,093,000
Investing CF
$0
Financing CF
$36,184,000
CapEx
$-167,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.17
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,623,711,000
Inventory
$105,124,000
Receivables
$140,190,000
ST Investments
—
EBIT TTM
$63,763,000
Pretax Income TTM
$-20,841,000
Interest Exp TTM
$84,604,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$418,244,000
EBITDA
$75,894,000
Free Cash Flow
$-49,706,376
Enterprise Value
$1,193,410,944
Total Cash
$156,158,000
Total Debt
$543,806,976
Shares Out
257,431,942
Trailing EPS
$0.00
Book Value
$-1.23
ROE
—
ROA
12.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 403,135,000 | 60,273,000 | -22,682,000 | 465,886,000 | 767,851,000 | — | -13,093,000 |
| Dec 2024 | 332,314,000 | 54,402,000 | -51,745,000 | 343,821,000 | 732,543,000 | — | -23,654,000 |
| Dec 2023 | 116,334,000 | -155,563,000 | -209,248,000 | 205,796,000 | 660,790,000 | — | -135,487,000 |
| Dec 2022 | 75,475,000 | -179,501,000 | -233,659,000 | 247,939,000 | 571,717,000 | — | -174,827,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.29
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | $803.32M | $3.69 | — |
| SPRY | ARS Pharmaceuticals, Inc. | $811.31M | $8.17 | — |
| LBRX | LB PHARMACEUTICALS INC | $812.41M | $28.33 | — |
| GERN | GERON CORP | $821.15M | $1.28 | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | $829.39M | $18.81 | — |
News headlines (Yahoo Finance, 1h cache)
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
2026-05-26 12:00 · Yahoo
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-05-14 20:30 · Yahoo
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
2026-05-14 14:44 · Yahoo
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
2026-05-13 12:00 · Yahoo
ARCHIMED to acquire Esperion Therapeutics in $1.1 billion deal
2026-05-01 15:13 · Yahoo
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
2026-05-01 12:28 · Yahoo
Esperion to be Acquired by ARCHIMED
2026-05-01 11:00 · Yahoo
Esperion to Report First Quarter 2026 Financial Results on May 7
2026-04-23 12:00 · Yahoo
Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference
2026-04-13 23:47 · Yahoo
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?
2026-04-09 15:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.